Results 261 to 270 of about 226,271 (312)

Podospora anserina target of rapamycin

Current Genetics, 2006
We have isolated the Podospora anserina TOR gene. The PaTOR protein displayed strong identities with TOR proteins from other eukaryotes especially in the FRB domain and the kinase domain. Genome analysis suggests that a single TOR gene exists in Podospora.
Pinan-Lucarré, B., Iraqui, I., Clavé, C.   +2 more
openaire   +3 more sources

Mechanistic Target of Rapamycin (mTOR) Inhibitors

2021
Mechanistic target of rapamycin (mTOR) inhibitors are macrocyclic lactone antibiotics derived from Streptomyces hygroscopicus that prevent T lymphocyte activation and B cell differentiation. Unlike calcineurin inhibitors (CNIs) that inhibit cytokine production, mTOR inhibitors block the cytokine signal transduction to arrest cells in the G1 to S phase.
Denise, Wang, Howard J, Eisen
openaire   +2 more sources

Targeting the molecular target of rapamycin (mTOR)

Current Opinion in Oncology, 2004
The molecular target of rapamycin, which is a member of the phosphoinositide 3-kinase related kinase family and a central modulator of cell growth, is a unique and prime strategic target for anticancer therapeutic development.The molecular target of rapamycin plays a critical role in transducing proliferative signals mediated through the ...
openaire   +2 more sources

Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis

Future Oncology, 2013
With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects.
Boers-Doets, C.B., Raber-Durlacher, J.E., Treister, N.S., Epstein, J.B., Arends, A.B.P., Wiersma, D.R., Lalla, R.V., Logan, R.M., van Erp, N.R.P., Gelderblom, H.   +9 more
openaire   +5 more sources

Therapeutic potential of target of rapamycin inhibitors

Expert Opinion on Therapeutic Targets, 2004
Target of rapamycin (TOR) functions within the cell as a transducer of information from various sources, including growth factors, energy sensors, and hypoxia sensors, as well as components of the cell regulating growth and division. Blocking TOR function mimics amino acid, and to some extent, growth factor deprivation and has a cytostatic effect on ...
John B, Easton, Peter J, Houghton
openaire   +2 more sources

Mammalian target of rapamycin (mTOR) inhibitors

Current Oncology Reports, 2004
Current efforts in anticancer drug development are targeting key factors in cell-cycle regulation. Mammalian target of rapamycin (mTOR) is one such protein kinase that facilitates cell growth by stimulating the cell to traverse the G1 to S phase of the cell cycle.
openaire   +2 more sources

Targeting the mammalian target of rapamycin in myxoid chondrosarcoma

Anti-Cancer Drugs, 2008
Myxoid chondrosarcoma is a slow-growing sarcoma poorly responsive to chemotherapy and radiation therapy. Translational research has validated several proteins as optional therapeutic targets. Significant responses are, however, rare. In this paper we report an extraordinary response of myxoid chondrosarcoma to targeted therapy by rapamycin in ...
Ofer, Merimsky, Rinat, Bernstein-Molho, Ronit, Sagi-Eisenberg   +2 more
openaire   +2 more sources

Inhibitors of the mammalian target of rapamycin

Expert Opinion on Investigational Drugs, 2005
The mammalian target of rapamycin (mTOR) is a downstream protein kinase of the phosphatidylinositol 3'-kinase-Akt signalling pathway. As a result of its position within this pathway and its central role in controlling cellular growth, mTOR is viewed as an important target for anticancer therapeutics development. Currently, the mTOR inhibitor rapamycin (
openaire   +2 more sources

Inhibitors of mammalian target of rapamycin

Drugs of the Future, 2001
The first generation of immunosuppressants such as azathioprine, steroids and anti-lymphocyte-globulins did not provide long-term graft survival in many transplant recipients. After the introduction of calcineurin inhibitors, solid organ transplantation became a standard therapy for many end-stage organ failures and immunosuppressive therapy was later ...
null Klupp, J., null Langrehr, J.M., null Junge, G., null Neuhaus, P.   +3 more
openaire   +1 more source

Common toxicities of mammalian target of rapamycin inhibitors

Targeted Oncology, 2011
The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities.
Scott A, Soefje, Anand, Karnad, Andrew J, Brenner   +2 more
openaire   +2 more sources